Cytochrome P450 Genotyping Panel
Also known as: CYP PANEL
Use
This test is used to assess genetic risk of abnormal drug metabolism for drugs metabolized by CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, and CYP3A5. It may aid in drug selection and dose planning for many drugs.
Special Instructions
Informed consent for genetic testing is required for NY patients. Counseling and informed consent are recommended for genetic testing. Consent forms are available online.
Limitations
Only the targeted variants will be detected by this panel. This test cannot detect all possible variants, and thus assumptions about phase and content are made to assign alleles. Diagnostic errors can occur due to rare sequence variations. The test result does not replace the need for therapeutic drug or clinical monitoring.
New York Approved
Methodology
PCR-based
Biomarkers
LOINC Codes
- 79715-9
- 79716-7
- 79714-2
- 78972-7
- 46724-1
- 57132-3
- 40425-1
- 81139-8
- 81140-6
- 66746-9
- 50398-7
- 72882-4
- 79720-9
- 81259-4
- 101785-4
- 79717-5
- 11526-1
Result Turnaround Time
5-10 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3 mL
Minimum Volume
1 mL
Container
Lavender (K2EDTA), pink (K2EDTA), or yellow (ACD solution A or B).
Storage Instructions
Preferred transport temp: Refrigerated.
Causes for Rejection
Plasma or serum. Specimens collected in sodium heparin or lithium heparin. Frozen specimens in glass collection tubes.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 3 days |
| Refrigerated | 1 week |
| Frozen | 1 month |